<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        12-584-10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RESCLAR 500MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLARITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        36.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NEOPHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NEOPHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NEOPHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Compo8ltlon<br />Active lngradlent:<br />Each lllm-coabld tabla! contains Clalfthromycln USP 25Cmg or 500mg.<br />IIIIIC!Ivalngradlanla:<br />Mlci&quot;OCIYSI8IIIne Cellulose, Colloidal Anhydrous Silica, Start:ll, PcNidone,<br />Croacarmelloee Sodiwn, Purified Talc, Stearic Acid, Magnesium Steanrte,<br />Polyvinyl Alcohol, Titanium Dioxide, PEG 3350, Lecithin, Indigo Carmine<br />Lake, Qlinoline Yellow Lake, Iron Chdde Yellow &amp; Purified Wet&laquo;.<br />Pleate read all the information in this leaflet<br />carvlully before you atart taking the medlcadon.<br />WJurtcto.. RNt:IM t.blrJtconlllln .nd haw cto../f-*?<br />Re&amp;clar tabla! contains clarilhromyocin, an antibio1ic belonging to a gruup<br />of drug~ called macrolides.<br />!i! Clalfthromycln wcrl!a by piiMintlng !he growth of csrtaln baci!Hia that<br />~ cause infections.<br />WJurt.,. ReacfM..,.,. ueed feN?<br />Reeclar lableta ara uaad lor !he management of Infections auch as:<br />&bull; Cheat lnlectlona, throat lnfactlona, alnus lnledlons.<br />&bull; Skin and 80ft tiaaue infection&amp;.<br />Re&amp;clar is also recommended by dcoiDR for treatilg infactions of<br />Helicobacter pylori associated duodenal ulcers.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You should be oareful totalra Resclartablets if you:<br />- are allergic to claritllromyan or other rTIIICIOiide drugs or any of the<br />ingredients lis1Bd il the composition<br />&middot; are taking medicin&amp;S such u ergotamine or dihydroergotamine<br />&bull; lllllfllr from kidney problema<br />&bull; lllllfllr from liver prcblems<br />N. clartlhrcmydn Is mainly eJCCretad by the liver and the kidneys, caution<br />should be axerclead In admlnlllllmg Reaclar to pstlenta wlltl Impaired<br />liver or klctley function. II any fll the ebavll Ia appllc.ble to you,<br />contact your d-before taldng Reeder tableta.<br />Prolonged or rapeatad adminilllralion ol clll&#39;i1hrornycin may resu~ in<br />auper-infaction. In auch cases, claritllromydn should be discontinued lllld<br />approprilllll1herapy ilslituted.<br />H. pyle~ may develop l1l8lelance to clalfthrcmydn.<br />CM ll&#39;HI*r flllllet. be ueed In fN8IIIIMICY .nd b18o11Nd111g?<br />W you are pr!918nl or braaatread~ an Infant, do not talr8 Re&amp;clar<br />tablets wltholll conaulllng your doctor ftnd.<br />Resdar tablets should not be used during pregnancy or braastfeading<br />unless !he benet~ is ClOI&#39;Isidarad to outweiltl the risk.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Depenclng upon 1118 type and 88Y8rlty of lnlacllon, your doctor will decide<br />the doee of Reeclar tablets<br />&bull; Tlks Resclar tabl&amp;b with at least haW a glass of wa1Br.<br />&bull; Do nat eJCC&amp;ad the sta1Bd dose.<br />The recommended doeagels as follows:<br />Artun.lllltl t:lllldn!ll OW!f&quot; 1R )&#39;Nnl at &quot;&#39;Il!<br />The usual dosage ia 250mg twice ddyfor 7 days. In aevere infection&amp;, your<br />doctor may inoreue 1he dosage to 500mg twice daily lor up to t4 day$.<br />.CIIIIdNn UtMf8l&quot; JR ,_.. at.,.<br />Resdar tabl&amp;b ere not AIIXJI!Imended in chilchn under t2 years of age.<br />Enldlcatlon at H. l&#39;ylorf In,.,.,. wlllr rlfloclaM/ ulorN<br />For the eradication of H. pylori, your doctor will recommend a combinalion of<br />diiTerant drugs. Conau~your doc:IDr, who will decide the type of combination<br />therapy that Ia su~ble for you. The usual racorrvn&amp;nded therapies Include:<br />FIHcllr lUll! DlugZ DlugS Dulllllln<br />~~llblst AmoldliltiXXImg<br />tt.t:eadl,- :::::&bull; :J)rg<br />7-t4days<br />::.~lablet =~~ :::::., :J)rg 7day$<br />One 500mg tablet AmoldliltiXXImgtwice Omeprazole 40mg 7days<br />IWice a day adayort.tat~~IIZDie a clay 400mgm&bull;<br />::.~~tablet =:~~1000mg Omeprazole 20mg<br />a claY<br />tO days<br />Ona~llblst ~p.ra: 40rG tak8n - t4daya<br />tine timet a day<br />The cormlnallon therapy recommended by your doc!Dr may diller from<br />the above racommend&amp;llona.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>W~Y~r llhould you do If you m1ae &bull; do8IJ at RIMellw raii.W?<br />II you lolget to take a do&amp;l, take another as aoon as you remember. Do<br />not talr8 more tablala In a day 1han whet your doctor advlead.</p><p>Whar.,. rile ~at Rut:/ar ..,.,_ on IIJe IJblllry to drive .nd<br />-IINICIIfnN7<br />Rarely dizziless has been niPOrted after takilg claritllromydn tablet. n<br />you feel dizzy after biking Resclar tablleti, do not drivll or use machines.<br />Wlu!t.,. the~ IRde,... wlllr lfNclar ,.,.,.,<br />Clarithromydn is generally well toleralad. Side ellec1s include nauaea,<br />dyspepsia, diarrhoea, vomiting, abdominal pain, paraeahaia, headache<br />arthralgia, and myalgia. Tongue dlacoklratlon, atom~la and giOIIIItla<br />have been niiJOrted. Allergic reactions to clarlthrornycln range from<br />urticaria, mild skin erup11ons 1o anaphyllllds and nnly S1even&amp;Johneon<br />ayndrome.t!xlc epidermal necrolyals. Thera haw been rare raporla ol<br />hypoglycaemla, acme ol which hive OCCIJmed In pallenta on ClOI&#39;ICUmlnl<br />oral hypoglycallmlc ageniB or Insulin.<br />Thera haw been raport ol transient CNS side aflacts include dizzin-.<br />vertigo, anxiety, insomnia, bad dreams, confusion, disorientation,<br />hallucinations, psychosis, depersonalisstion. Thera have been f8110rla ol<br />hearing 10118 which ill usually nMIIIIible on withdrawal of therapy. lsolalad<br />Cl188l ollaucopoenia and 1hronDx:ytopania have been f8110rled.<br />M with other macrolldaa, hepallc dysfunction (uaually ravaralble) haa<br />been repelled. Dysfunction may be aevete and very rarely tatal hepetit<br />failure has been reported.<br />The following side ~ hBYB been n~PCrted rarely-increased serum<br />CIINIIinine, interltitial nephritis, renal failure, pancn~~~titis, conNaiona, QT<br />prolongation, ventricular tachycardia and Toraacles d&amp;S Poinl&amp;l.</p><p>WIY!r.,. the drup 111at can ~with,_,.,.,.,.,_,.<br />- In patlsniB receiving t:heophylllne, co~ administration<br />ol clarlthromydn may be asaoclatad with I11C188811 In &amp;Srum<br />theophylline conoantratlona.<br />- Rhabdornyolylle haa b11811 reported wl1h !he co-administration<br />ol clarllhrornycln wl1h Hr.tG CoA raductaae lnhlbllonl euch as<br />l-In and llrnveatdn.<br />- The uee of claritllrom)&#39;Cin in patieniB receivilg warfa~n may resu~ in<br />the potentiation of the ellects ol warfarin. Prothrombin time should<br />be frequently moritDrad il th-caMS.<br />- The ellecls of dlgoaln may be potantiatlld when co-admilistenld<br />wnh claritllromydn<br />- Clarithromycin may potential&amp; the efl&#39;ecta ol oal1llrnllzllplne.<br />- Sim!JtaniiOUB oral adminiatralion ol clarHhrornycin and zlclovucllna<br />to HIV infeclacl aduH patients may rasun in decraiiSIId steady sta111<br />levels ot zidowdine. This can be avoided by separaling 1118 doe&amp;<br />administration ot the druge by 1-2 houn1.<br />- While concurrently admlnlste~ng ~navlr and clarlthrornycln<br />In ranally mpalrad pstleniB, 1118 fallowing doae adjustmeniB ol<br />clarlthromycln should be conaldarad.<br />ct.... 30 1o 60mlhnln - reduce doae of clarlthromycln by 50%. Cla,<br />&lt;slinVInto - racU:e doae of clarllhromycln by 75%. Doa&amp;l grealllr !Mil<br />1gmlday ol clalfth~ should not be co-Mmlnlstllred wl1h rltonavlr.<br />If you are biking any of the above medications, inform your doctor or<br />pharmacist, who will naoommend appropriately.<br />What Mould yau do In ca&bull; of an atlf!l&#39;flou(Je?<br />In C8&amp;l of a overdosage, ee&amp;k lmmeclata medical _,lion.<br />Reports indicabl that ingestion of large amounts of clarithromydn can<br />be l!llp8Ciad to produoa gastrointestinal ~ms. Adverse reactions<br />accompanying owrdoaaQe should be tnlllted wi1h gastric IIMig&amp; and<br />supporlivii111888Urae.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Reeclar tablala should be stored il a dry place below 30&#39;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>na</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                na
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>neophanna, Abu Dhalbi, UAE</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                02/2006
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>na</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>na</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>na</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>na</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>na</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>na</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>na</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>na</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            na
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Resclar Tablets 500 mg.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains Clarithromycin USP 500 mg.
'for full list of excipients, see section 6.1'
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fi lm-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Consideration should be given to official guidance on the appropriate use of antibacterial<br />agents.<br />Clarithromycin 500mg Tablets are indicated in adults and children 12 years and older.<br />Clarithromycin is indicated for treatment of infections caused by susceptible organisms.<br />Indications include:<br />Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia.<br />Upper respiratory tract infections for example, sinusitis and pharyngitis.<br />Clarithromycin is appropriate for initial therapy in community acquired respiratory infections<br />and has been shown to be active in vitro against common and atypical respiratory<br />pathogens as listed in the microbiology section.<br />Clarithromycin is also indicated in skin and soft tissue infections of mild to moderate<br />severity.<br />Clarithromycin in the presence of acid suppression effected by omeprazole or lansoprazole is<br />also indicated for the eradication of H. pylori in patients with duodenal ulcers.<br />Clarithromycin is usually active against the following organisms in vitro:<br />Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible); Streptococcus<br />pyogenes (Group A beta-hemolytic streptococci); alpha-hemolytic streptococci (viridans<br />group); Streptococcus (Diplococcus) pneumoniae;Streptococcus agalactiae; Listeria<br />monocytogenes.</p><p>Gram-&#39;negative Bacteria : Haemophilus influenzae; Haemophilus parainfluenzae; Moraxella<br />(Branhamella) catarrhalis; Neisseria gonorrhoeae; Legionella pneumophila; Bordetella<br />pertussis; Helicobacter pylori; Campylobacter jejuni.<br />Mycoplasma : Mycoplasma pneumoniae; Urea plasma urealyticum.<br />Other Organisms: Chlamydia trachomatis; Mycobacterium avium; Mycobacterium leprae.<br />Anaerobes: Macrolide-susceptible Bacteroides tragi/is; Clostridium perfringens; Peptococcus<br />species; Peptostreptococcus species; Propionibacterium acnes.<br />Clarithromycin has bactericidal activity against several bacterial strains. The organisms<br />include Haemophi/us influenzae; Streptococcus pneumoniae; Streptococcus pyogenes;<br />Streptococcus agalactiae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; H.<br />pylori and Campylobacter spp.<br />The activity of clarithromycin against H. pylori is greater at neutral pH than at acid pH.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients with respiratory tract/skin and soft tissue infections.<br />Adults&middot;: The usual dose is 250 mg twice daily although this may be increased to SOOmg<br />twice daily in severe infections. The usual duration of treatment is 6 to 14 days.<br />Children older than 12 years: As for adults.<br />Children younger than 12 years:<br />Use of Klaricid SOOmg Tablets are not recommended for children younger than 12 years.<br />Clinical trials have been conducted using clarithromycin paediatric suspension in children 6<br />months to 12 years of age. Therefore, children under 12 years of age should use<br />clarithromycin paediatric suspension (granules for oral suspension).<br />Eradication of H. pvlori in patients with duodenal ulcers (Adults)<br />The usual duration of treatment is 6 to 14 days.<br />Triple Therapy<br />Clarithromycin (SOOmg) twice daily and lansoprazole 30mg twice daily should be given with<br />amoxycillin 1000mg twice daily.<br />Triple Therapy<br />Clarithromycin (SOOmg) twice daily and lansoprazole 30mg twice daily should be given with<br />metronidazole 400mg twice daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clarithromycin is contra-indicated in patients with known hypersensitivity to macrolide
antibiotic drugs or to any of its excipients. Concomitant administration of clarith romycin and
ergotamine or dihydroergotamine is contraindicated, as this may result in ergot toxicity.
Concomitant administration of clarithromycin and any of the following drugs is
contraindicated: astemizole, cisapride, pimozide and terfenadine as this may result in QT
prolongation and cardiac arrhythmias, including ventricular tachycardia, ventricular
fibri llation, and torsades de pointe.
Clarithromycin should not be given to patients with history of QT prolongation or ventricular
cardiac arrhythmia, including torsades de pointe.
Concomitant administration with ticagrelor or ranolazine is contraindicated. Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors
(statin.s) that are extensively metabolized by CYP3A4, (lovastatin or simvastatin), due to the
increased risk of myopathy, including rhabdomyolysis.
As with other strong CYP3A4 inhibitors, Clarithromycin should not be used in patients taking
colchicine.
Clarithromycin should not be given to patients with hypokalaemia (risk of prolongation of
QT-time).
Clarithromycin should not be used in patients who suffer from severe hepatic failure in
combination with renal impairment.Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors
(statin.s) that are extensively metabolized by CYP3A4, (lovastatin or simvastatin), due to the
increased risk of myopathy, including rhabdomyolysis.
As with other strong CYP3A4 inhibitors, Clarithromycin should not be used in patients taking
colchicine.
Clarithromycin should not be given to patients with hypokalaemia (risk of prolongation of
QT-time).
Clarithromycin should not be used in patients who suffer from severe hepatic failure in
combination with renal impairment.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The physician should not prescribe clarithromycin to pregnant women without carefully<br />weighing the benefits against risk, particularly during the first three months of pregnancy.<br />Caution is advised in patients with severe renal insufficiency. Clarithromycin is principally<br />excreted by the liver. Therefore, caution should be exercised in administering this antibiotic<br />to patients with impaired hepatic function. Caution should also be exercised when<br />administering clarithromycin to patients with moderate to severe renal impairment.<br />Cases &middot;of fata l hepatic failure have been reported. Some patients may have had pre-existing<br />hepatic disease or may have been taking other hepatotoxic medicinal products. Patients<br />should be advised to stop treatment and contact their doctor if signs and symptoms of<br />hepatic disease develop, such as anorexia, jaundice, dark urine, pruritus, or tender<br />abdomen.<br />Pseudomembranous colit is has been reported with nearly all antibacterial agents, including<br />macrolides, and may range in severity from mild to lifethreatening.<br />Clostridium diffici/e- associated diarrhoea (CDAD) has been reported with use of nearly all<br />antibacterial agents including clarithromycin, and may range in severity from mild diarrhoea<br />to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon,<br />which may lead to overgrowth of C. difficile. CDAD must be considered in all patients who<br />present with diarrhea following antibiotic use. Careful medical history is necessary since<br />CDAD has been reported to occur over two months after the administration of antibacterial<br />agents. Therefore, discontinuation of clarithromycin therapy should be considered<br />regardless of the indication.<br />Microbial testing should be performed and adequate treatment initiated. Drugs inhibiting<br />peristalsis should be avoided.&nbsp;There have been post-marketing reports of colchicine toxicity with concomitant use of<br />clarithromycin and colchicine, especially in the elderly, some of which occurred in patients<br />with renal insufficiency. Deaths have been reported in some such patients. Concomitant<br />administration of clarithromycin and colchicine is contraindicated.<br />Caution is advised regarding concomitant administration of clarithromycin and<br />triazo lobenzodiazepines, such as triazolam, and midazolam.<br />Caution is advised regarding concomitant administration of clarithromycin with other<br />ototoxic drugs, especially with aminoglycosides. Monitoring of vestibular and auditory<br />function should be carried out during and after treatment.<br />Due to the risk for QT prolongation, clarithromycin should be used with caution in patients<br />with coronary artery disease, severe cardiac insufficiency, hypomagnesaemia, bradycardia<br />(&lt;50 bpm), or when co-administered with other medicinal products associated with QT<br />prolongation. Clarithromycin must not be used in patients with congenital or documented<br />acquired QT prolongation or history of ventricular arrhythmia.<br />Pneumonia: In view of the emerging resistance of Streptococcus pneumoniae to macrolides,<br />it is important that sensitivity testing be performed when prescribing clarithromycin for<br />community-acquired pneumonia. In hospital acquired pneumonia, clarithromycin should be<br />used in combination with additional appropriate antibiotics.<br />Skin and soft t issue infections of mi ld to moderate severity: These infections are most often<br />caused by Staphylococcus aureus and Streptococcus pyogenes, both of which may be<br />resistant to macrolides. Therefore, it is important that sensitivity testing be performed. In<br />cases where beta-lactam antibiotics cannot be used (e.g . allergy), other antibiotics, such as<br />cl indamycin, may be the drug of first choice. Currently, macrolides are only considered to<br />play a role in some skin and soft tissue infections, such as those caused by<br />Corynebacterium minutissimum, acne vulgaris, and erysipelas and in situations where<br />penicillin treatment cannot be used.<br />In the event of severe acute hypersensitivity reactions, such as anaphylaxis, StevensJohnson<br />Syndrome, toxic epidermal necrolysis, DRESS and Henoch-Schonlein purpura,<br />clarithromycin therapy should be discontinued immediately and appropriate treatment<br />should be urgently initiat ed.<br />Clarithromycin should be used with caution when administered concurrently with medication that inducethe cytochrome&nbsp; CYP3A4 ENZYME&nbsp;HMG-CoA Reductase Inhibitors (statins): Concomitant use of clarithromycin with lovastatin<br />or simvastatin is contraindicated.Caution should be exercised when prescribing<br />clarithromycin with other statins. Rhabdomyolysis has been reported in patients taking<br />clarithromycin and statins. Patients should be monitored for signs and symptoms of<br />myopathy.<br />In situations where the concomitant use of clarithromycin with statins cannot be avoided, it<br />is recommended to prescribe the lowest registered dose of the statin. Use of a statin that is<br />not dependent on CYP3A metabolism (e.g. fluvastatin) can be considered.<br />Oral hypoglycaemic agents/Insulin: The concomitant use of clarithromycin and oral<br />hypoglycaemic agents (such as sulphonylurias) and/or insulin can result in significant<br />hypoglycaemia. Careful monitoring of glucose is recommended.<br />Oral anticoagulants: There is a risk of serious haemorrhage and significant elevations in<br />International Normalized Ratio (INR) and prothrombin time when clarithromycin is coadministered<br />with warfarin.INR and prothrombin times should be frequently monitored while<br />patients are receiving clarithromycin and oral anticoagulants concurrently.<br />Use of any antimicrobial therapy, such as clarithromycin, to treat H. pylori infection may<br />select for drug-resistant organisms.<br />Long-term use may, as with other antibiotics, result in colonisation with increased numbers<br />of non-susceptible bacteria and fungi. If superinfections occur, appropriate therapy should<br />be instituted.<br />Attention should also be paid to the possibility of cross resistance between clarithromycin<br />and other macrolide drugs, as well as lincomycin and clindamyci n.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of the following drugs is strictly contraindicated due to the potential for<br />severe drug interaction effects:<br />Cisapride. pimozide. astemizole and terfenadine:<br />Elevated cisapride levels have been reported in patients receiving clarithromycin and<br />cisapride concomitantly .. This may result in QT prolongation and cardiac arrhythmias<br />including ventricular tachycardia, ventricular fibrillation and torsades de pointes. Similar<br />effects have been observed in patients taking clarithromycin and pimozide concomitantly.<br />Macrolides have been reported to alter the metabolism of terfenadine resulting in increased<br />levels of terfenadine which has occasionally been associated with cardiac arrhythmias, such&nbsp;as QT prolongation, ventricular tachycardia, ventricular fibrillation and torsades de pointes.<br />In one study in 14 healthy volunteers, the concomitant administration of clarithromycin and<br />terfenadine resulted in 2- to 3-fold increase in the serum level of the acid metabolite of<br />terfenadine and in prolongation of the QT interval which did not lead to any clin ica lly<br />detectable effect. Simi lar effects have been observed with concomitant administration of<br />astemizole and other macrolides.<br />Ergot amine/dihydroergotamine:<br />Post- marketing reports indicate that co-administration of clarithromycin with ergotamine or<br />dihydroergotamine has been associated with acute ergot toxicity characterized by<br />vasospasm, and ischaemia of the extremities and other tissues including the central nervous<br />system. Concomitant administration of clarithromycin and these medicinal products is<br />contraindicated .<br />HMG-CoA Reductase Inhibitors (statins)<br />Concomitant use of clarithromycin with lovastatin or simvast atin is contraindicated as these<br />statins are extensively metabolized by CYP3A4 and concomitant treatment with<br />clarithromycin increases their plasma concentration, which increases the risk of myopathy,<br />including rhabdomyolysis. Reports of rhabdomyolysis have been received for patients<br />taking clarit hromycin concomitantly with these st atins. If treatment with clarithromycin<br />cannot be avoided, therapy with lovastatin or simvastatin must be suspended during the<br />course of treatment.<br />Caution should be exercised when prescribing clarithromycin with statins. In situations<br />where the concom itant use of clarithromycin with statins cannot be avoided, it is<br />recommended to prescribe the lowest registered dose of the stat in. Use of a statin that is<br />not dependent on CYP3A metabolism (e.g .f luvastatin) can be considered. Patients should be<br />monitored for signs and symptoms of myopathy.<br />Effects of Other Medicinal Products on Clarithromvcin<br />Drugs that are inducers of CYP3A (e.g. rifampicin, phenytoin, carbamazepi ne,<br />phenobarbita l, St John&#39;s wort) may induce the metabolism of clarithromycin . This may<br />result in sub-therapeutic levels of clarithromycin leading to reduced efficacy. Furthermore, it<br />might be necessary to monitor the plasma levels of the CYP3A inducer, which could be<br />increased owi ng to t he inhibition of CYP3A by clarit hromycin (see also the relevant product information for the CYP3A4 inhibtor administered. Concomitant administration of rifabutin&nbsp;and clarithromycin resulted in an increase in rifabutin, and decrease in clarithromycin serum<br />levels together with an increased risk of uveitis.<br />The fo llowing drugs are known or suspected to affect circulating concentrations of<br />clarithromycin; clarithromycin dosage adjustment or consideration of alternative treatments<br />may be required.<br />Efavirenz, nevirapine, rifampicin, rifabutin and rifapentine<br />Strong inducers of the cytochrome P450 metabolism system such as efavirenz, nevirapine,<br />rifampicin, rifabutin, and rifapentine may accelerate the metabolism of clarithromycin and<br />thus lower the plasma levels of clarithromycin, while increasing those of 14-0H<br />clarithromycin, a metabolite that is also microbiologically active. Since the microbiological<br />activit ies of clarithromycin and 14-0H-clarithromycin are different for different bacteria, the<br />intended therapeutic effect could be impaired during concomitant administration of<br />clarithromycin and enzyme inducers.<br />Etravirine<br />Clarithromycin exposure was decreased by etravirine; however, concentrations of the active<br />metabolite, 14-0H-clarithromycin, were increased. Because 14- OH-clarithromycin has<br />reduced activity against Mycobacterium avium complex (MAC), overall activity against this<br />pathogen may be altered; therefore alternatives to clarithromycin should be considered for<br />the tr~atment of MAC.<br />Fluconazole<br />Concomitant administration of fluconazole 200 mg daily and clarithromycin 500 mg twice<br />daily to 21 healthy volunteers led to increases in the mean steady-state minimum<br />clarithromycin concentration (Cmin) and area under the curve (AUC) of 33% and 18%<br />respectively. Steady state concentrations of the active metabolite 14-0H-clarithromycin<br />were not significantly affected by concomitant administration of fluconazole. No<br />clarithromycin dose adjustment is necessary.<br />Ritonavir<br />A pharmacokinetic study demonstrated that the concomitant administration of ritonavir 200<br />mg every eight hours a.nd clarithromycin 500 mg every 12 hours resulted in a marked<br />inhibit ion of the metabolism of clarithromycin. The clarithromycin Cmax increased by 31%,<br />Cmin increased 182% and AUC increased by 77% with concomitant administration of<br />ritonavir. An essentially complete inhibition of the formation of 14-0H-clari thromycin was&nbsp;noted. Because of the large therapeutic window for clarithromycin, no dosage reduction<br />should be necessary in patients with normal renal function. However, for patients with renal<br />impairment, the following dosage adjustments should be considered: For patients with CLCR<br />30 to 60 mL/min the dose of clarithromycin should be reduced by 50%. For patients with<br />CLCR &lt;30 mL/min the dose of clarithromycin should be decreased by 75%. Doses of<br />clarithromycin greater than 1 gm/day should not be co-administered with ritonavir.<br />Similar dose adjustments should be considered in patients with reduced renal function when<br />ritonavir is used as a pharmacokinetic enhancer with other HIV protease inhibitors including<br />atazanavir and saquinavir.<br />Effect of Clarithromycin on Other Medicinal Products<br />CYP3A-based interactions<br />Co-administration of clarithromycin, known to inhibit CYP3A, and a drug primarily<br />metabolised by CYP3A may be associated with elevations in drug concentrations that could<br />increase or prolong both therapeutic and adverse effects of the concomitant drug.<br />Clarithromycin should be used with caution in patients receiving treatment with other drugs<br />known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow<br />safety margin (e.g. carbamazepine) and/or the substrate is extensively metabolised by this<br />enzyme.<br />Dosage adjustments may be considered, and when possible, serum concentrations of drugs<br />primarily metabolised by CYP3A should be monitored closely in patients concurrently<br />receiving clarithromycin.<br />The fol lowing drugs or drug classes are known or suspected to be metabolised by the same<br />CYP3A isozyme: alprazolam, astemizole, carbamazepine, ci lostazol, cisapride, ciclosporin,<br />disopyramide, ergot alkaloids, lovastatin, methylprednisolone, midazolam, omeprazole, oral<br />anticoagulants (e.g.warfarin), pimozide, quinidine, rifabutin, sildenafil, simvastatin,<br />sirolimus, tacrolimus, terfenadine, triazolam and vinblastine. Drugs interacting by similar<br />mechanisms through other isozymes within the cytochrome P450 system include phenytoin,<br />theophylline and valproate.<br />Antiarrhythmics<br />There have been post-marketed reports of torsades de pointes occurring with the<br />concurrent use of clarithromycin and quinidine or disopyramide. Electrocardiograms should<br />be monitored for QT prolongation during coadministration of clarithromycin with these&nbsp;drugs. Serum levels of quinidine and disopyramide should be monitored during<br />clarithromycin therapy.<br />There have been post marketing reports of hypoglycemia with the concomitant<br />administration of clarithromycin and disopyramide. Therefore blood glucose levels should be<br />monitored during concomitant administration of clarithromycin and disopyramide.<br />Oral hypoglycemic agents/Insulin<br />With certain hypoglycemic drugs such as nateglinide, and repaglinide, inhibition of CYP3A<br />enzyme by clarithromycin may be involved and could cause hypolgycemia when used<br />concomitantly. Careful monitoring of glucose is recommended.<br />Omeprazole<br />Clarithromycin (500 mg every 8 hours) was given in combination with omeprazole ( 40 mg<br />daily) to healthy adult subjects. The steady-state plasma concentrations of omeprazole were<br />increased (Cmax, AUC0-24, and tl/2 increased by 30%, 89%, and 34%, respectively), by<br />the concomitant administration of clarithromycin. The mean 24-hour gastric pH value was<br />5.2 when omeprazole was administered alone and 5. 7 when omeprazole was coadministered<br />with clarithromycin.<br />Sildenafil, tadalafil and vardenafil<br />Each of these phosphodiesterase inhibitors is metabolised, at least in part, by CYP3A, and<br />CYP3A may be inhibited by concomitantly administered clarithromycin. Co-administration of<br />clarithromycin with sildenafil, tadalafil or vardenafil would likely result in increased<br />phosphodiesterase inhibitor exposure. Reduction of sildenafil, tadalafil and vardenafil<br />dosages should be considered when these drugs are co-administered with clarithromycin.<br />Theophylline, carbamazepine<br />Results of clin ical studies indicate that there was a modest but statistically significant<br />(p:50.05) increase of circulating theophylline or carbamazepine levels when either of these<br />drugs were administered concomitantly with clarithromycin. Dose reduction may need to be<br />considered.<br />Tolterodine<br />The primary route of metabolism for tolterodine is via the 206 isoform of cytochrome P450<br />(CYP2D6). However, in a subset of the population devoid of CYP2D6, the identified pathway<br />of metabolism is via CYP3A. In this population subset, inhibition of CYP3A results in<br />significantly higher serum concentrations of tolterodine. A reduction in tolterodine dosage<br />may be necessary in the presence of CYP3A inhibitors, such as clarithromycin in the&nbsp;CYP2D6 poor metaboliser population.<br />Triazolobenzodiazepines (e.g., alprazolam. midazolam, triazolam)<br />When midazolam was co-administered with clarithromycin tablets (500 mg twice daily),<br />midazolam AUC was increased 2. 7-fold after intravenous administration of midazolam and<br />7-fold after oral administration. Concomitant administration of oral midazolam and<br />clarithromycin should be avoided. If intravenous midazolam is co-administered with<br />clarithromycin, the patient must be closely monitored to allow dose adjustment. The same<br />precautions should also apply to other benzodiazepines that are metabolised by CYP3A,<br />including triazolam and ~ lprazol am. For benzodiazepines which are not dependent on CYP3A<br />for their elimination (temazepam, nitrazepam, lorazepam), a clinically important interaction<br />with clarithromycin is unlikely.<br />There have been post-marketing reports of drug interactions and central nervous system<br />(CNS) effects (e.g., somnolence and confusion) with the concomitant use of clarithromycin<br />and triazolam. Monitoring the patient for increased CNS pharmacological effects is<br />suggested.<br />Other drug interactions<br />Aminoglycosides<br />Caution is advised regarding concomitant administration of clarithromycin with other<br />ototoxic drugs, especially with aminoglycosides.<br />Colchicine<br />Colchicine is a substrate for both CYP3A and the efflux transporter, Pglycoprotein (Pgp).<br />Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. When<br />clarithromycin and colchicine are administered together, inhibition of Pgp and/or CYP3A by<br />clarithromycin may lead .to increased exposure to colchicine. Patients should be monitored<br />for clinical symptoms of colchicine toxicity.<br />Digoxin<br />Digoxin is thought to be a substrate for the efflux transporter, P-glycoprotein (Pgp).<br />Clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are administered<br />together, inhibition of Pgp by clarithromycin may lead to increased exposure to digoxin.<br />Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin<br />concomitantly have also been reported in post marketing surveillance. Some patients have<br />shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias.&nbsp;Serum digoxin concentrations should be carefu lly monitored while patients are receiving<br />digoxin and clarithromycin simultaneously.<br />Zidovudine<br />Simultaneous oral administration of clarithromycin tablets and zidovudine to HIV- infected<br />adult patients may result in decreased steady-state zidovudine concentrations. Because<br />clarithromycin appears to interfere with the absorption of simultaneously administered oral<br />zidovudine, this interaction can be largely avoided by staggering the doses of clarithromycin<br />and zidovudine to allow for a 4-hour interval between each medication. This interaction does<br />not appear to occur in paediatric HIV- infected patients taking clari thromycin suspension<br />with zidovudine or dideoxyinosine. This interaction is unl ikely when clarithromycin is<br />administered via intravenous infusion.<br />Phenytoin and Valproate<br />There have been spontaneous or published reports of interactions of CYP3A inhibitors,<br />including clarithromycin with drugs not thought to be metabolised by CYP3A (e.g. phenytoin<br />and valproate). Serum level determinations are recommended for these drugs when<br />administered concomitantly with clarithromycin . Increased serum levels have been<br />reported.<br />Bi-directional drug interactions<br />Atazanavir<br />Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is<br />evidence of a bi-directional drug interaction. Co-administrat ion of clarithromycin (500 mg<br />twice daily) with atazanavir ( 400 mg once daily) resulted in a 2-fold increase in exposure to<br />clarithromycin and a 70% decrease in exposure to 14-0H-clarithromycin, with a 28%<br />increase in the AUC of atazanavir. Because of the large therapeut ic window for<br />clarithromycin, no dosage reduction should be necessary in patients with normal renal<br />fu nct ion.For patients with moderate renal function (creatinine clearance 30 to 60 mL/min),<br />the dose of clarithromycin should be decreased by 50%. For patients with creatinine<br />clearance &lt;30 mL/min, the dose of clarithromycin should be decreased by 75% using an<br />appropriate clarithromycin formulation . Doses of clarithromycin greater than 1000 mg per<br />day should not be co-administered with protease inhibitors.&nbsp;Calcium Channel Blockers<br />Caution is advised regarding the concomitant administration of clarithromycin and ca lcium<br />channel blockers metabolized by CYP3A4 (e.g. verapamil, amlodipine, di ltiazem) due to the<br />risk of hypotension. Plasma concentrations of clarithromycin as well as calcium channel<br />blockers may increase due to the interaction. Hypotension, bradyarrhythmias and lactic<br />acidosis have been observed in patients taking clarithromycin and verapamil concomitantly.<br />Itraconazole<br />Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, leading to a<br />bidirectional drug interaction. Clarithromycin may increase the plasma levels of itraconazole,<br />while itraconazole may increase the plasma levels of clarithromycin. Patients taking<br />itraconazole and clarithromycin concomitantly should be monitored closely for signs or<br />symptoms of increased or prolonged pharmacologic effect.<br />Saquinavir<br />Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A, and there is<br />evidence of a bi -directional drug interaction. Concomitant administration of clarithromycin<br />(500 mg twice daily) and saquinavir (soft gelatin capsules, 1200 mg three times daily) to 12<br />healthy volunteers resulted in steady-state AUC and Cmax values of saquinavir which were<br />177% and 187% higher than those seen with saquinavir alone. Clarithromycin AUC and<br />Cmax values were approximately 40% higher than those seen with clarithromycin alone. No<br />dose adjustment is required when the two drugs are co-administered for a limited time at<br />the doses/formulations studied. Observations from drug interaction studies using the soft<br />gelatin capsule formulation may not be representative of the effects seen using the<br />saquinavir hard gelatin capsule. Observations from drug interaction studies performed with<br />saquinavir alone may not be representative of the effects seen with saquinavir/ritonavir<br />therapy. When saquinavir is co-administered with ritonavir, consideration should be given to<br />the potential effects of ritonavir on clarithromycin.<br />Clarithromycin has been shown not to interact with oral contraceptives.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The safety of clarithromycin for use during pregnancy has not been established. Based on<br />variable results obtained from studies in mice, rats, rabbits and monkeys, the possibility of&nbsp;adverse effects on embryofoetal development cannot be excluded. Therefore, use during<br />pregnancy is not advised without carefully weighing the benefits against risk.<br />Breast-feeding<br />The safety of clarithromycin for using during breast-feeding of infants has not been<br />established. Clarithromyci n is excreted into human breast milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on the effect of clarithromycin on the ability to drive or use machines.<br />The potential for dizziness, vertigo, confusion and disorientation, which may occur with the<br />medication, should be taken into account before patients drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a. Summary of the safety profile<br />The most frequent and common adverse reactions related to clarithromycin therapy for both<br />adult and paediatric populations are abdominal pain, diarrhoea, nausea, vomiting and taste<br />perversion. These adverse reactions are usually mi ld in intensity and are consistent with the<br />known safety profile of macrolide antibiotics.<br />There was no significant difference in the incidence of these gastrointestinal adverse<br />reactions during cl inical tria ls between the patient population with or without pre-existing<br />mycobacterial infections.</p><p>b. Tabulated summary of adverse reactions<br />The following table displays adverse reactions reported in clinical trials and from postmarketing<br />experience with clarithromycin immediate-release tablets, granules for oral<br />suspension, powder for solution for injection, extended-release tablets and modified-release<br />tablets.<br />The reactions considered at least possibly related to clarithromycin are displayed by system<br />organ class and frequency using the following convention : very common (;:::1/10), common<br />(;::: 1/100 to&lt; 1/10), uncommon (;:::1/1,000 to&lt; 1/100) and not known (adverse reactions<br />from post- marketing experience; cannot be estimated from the available data). Within each<br />frequency grouping, adverse reactions are p</p><p>resented in order of decreasing seriousness<br />when the seriousness could be assessed.</p><p>rgan Class C!:1/10<br />&lt;1/10<br />&lt;!:1/1000 to &lt;1/100<br />the available data)<br />Cellulitis1<br />,<br />Infections &amp; candidiasis, Pseudomembranous<br />infestations gastroenteritis2<br />, colit is,erysipelas,<br />infection3,vaginal infection<br />Blood and Leukopenia,<br />lymphatic neutropenia4<br />, Agranu locytosis,<br />system t hrombocythaemia3<br />, thrombocytopenia<br />eosinophilia4<br />Immune Anaphylactoid<br />system reaction1<br />,<br />Anaphylactic reaction.<br />disorders5 hypersensitivity angioedema<br />Metabolism<br />and nutrition Anorexia, decreased<br />disorders appetite<br />Psychotic disorder,<br />Anxiety,<br />confusional state,<br />Psychiatric<br />Insomnia nervousness3<br />,<br />depersonalisation,<br />disorders<br />screaming3 depression,<br />disorientat ion,<br />hallucination,<br />abnormal dreams<br />Nervous<br />Dysgeusia, Loss of<br />Convulsion, ageusia,<br />headache, consciousness1<br />, system<br />taste dyskinesia1<br />,<br />parosmia, anosmia,<br />disorders<br />perversion dizziness,<br />paraesthesia<br />somnolence6, tremor<br />Ear and Vertigo, hearing<br />labyrinth impaired, t innitus<br />Deafness<br />disorders<br />Cardiac arrest1<br />,<br />Cardiac<br />atrial fibrillation 1<br />, Torsades de pointes7<br />,<br />disorders electrocardiogram ventricular<br />QT prolonged7<br />, tachycardia 7<br />extrasystoles1<br />,<br />palpitations<br />Vascular<br />HaemorrhageS<br />disorders Vasodilation 1<br />Respiratory,<br />Asthma 1<br />, epistaxis2<br />, thoracic and<br />mediastinal<br />pulmonary<br />disorder embolism</p><p>i?!1/100 to be estimated from<br />Organ Class i?!1/10<br />&lt; 1/10<br />i?!1/1000 to &lt; 1/ 100<br />the available data)<br />Oesophagit is1<br />,<br />Diarrhoea9<br />,<br />gastro esophageal<br />reflux disease2<br />,<br />vomiting,<br />gastritis, proctalgia2<br />, Pancreatitis acute,<br />Gastrointestinal dyspepsia,<br />stomatitis, glossitis, tongue discolouration,<br />disorders nausea, abdominal<br />abdominal tooth discolouration<br />pain<br />distension4,<br />constipation, dry<br />mouth, eructation,<br />f latulence<br />Hepatobiliary Liver Cholestasis4<br />, Hepatic failure10<br />,<br />disorders function test hepatitis4<br />, alanine jaundice<br />abnormal aminotransferase hepatocellular<br />increased, aspartate<br />aminotransferase<br />increased,gammaglutamyl<br />transferase<br />increased4<br />Skin and Rash, Dermatit is bullous1, Stevens-Johnson<br />subcutaneous hyperhidrosis pruritus, urticaria, syndromeS, toxic<br />tissue rash maculopapularl epidermal necrolysis5,<br />disorders drug rash with<br />eosinophilia and<br />systemic symptoms<br />(DRESS), acne<br />Musculoskel Muscle spasms3<br />, Rhabdomyolysis2,11 **,<br />etal and musculoskeletal myopathy<br />connect ive stiffness!, myalgia2<br />tissue<br />disorders<br />Renal and Blood creatinine Renal failure,<br />urinary increased 1<br />, blood nephritis interstit ial<br />disorders urea increased1<br />General Injection site I njection site Malaise4<br />, pyrexia3<br />,<br />disorders and phlebitis1 pain1<br />, asthenia, chest pain4,<br />administration injection site chills4, fatigue4<br />site inflammation1<br />conditions<br />I nvestigations Albumin globulin International<br />ratio abnormal1<br />, normalised ratio<br />blood alkaline increased8<br />,<br />phosphatase prothrombin time<br />increased4<br />, prolonged8<br />, urine<br />blood lactate colour abnormal<br />dehydrogenase<br />increased4.</p><p>1 ADRs reported only for the Powder for Solution for Injection formulation<br />2ADRs&middot; reported only for the Extended-Release Tablets formulation<br />3 ADRs reported only for the Granules for Oral Suspension formulation<br />..._. .....d.. . Ju _9&quot;1-~.!~<br />neopharma<br />4 ADRs reported only for the Immediate-Release Tablets formulation 5<br />&bull;<br />7<br />&bull;<br />9<br />&bull;<br />10 See section a)<br />6<br />&bull;<br />8<br />&bull;<br />11 See section c)<br />* Because these reactions are reported voluntarily from a population of uncertain size, it is<br />not always possible to reliably estimate their frequency or establish a causal relationship to<br />drug exposure. Patient exposure is estimated to be greater than 1 billion patient treatment<br />days for c/arithromycin.<br />**In some of the reports of rhabdomyolysis, clarithromycin was administered concomitantly<br />with other drugs known to be associated with rhabdomyolysis (such as statins, fibrates,<br />colchicine or allopurinol):<br />c. Description of selected adverse reactions<br />Injection site phlebitis, injection site pain, vessel puncture site pain, and inject ion site<br />inflammation are specific to the clarithromycin intravenous formulation.<br />In some of the reports of rhabdomyolysis, clarithromycin was administered concomitantly<br />with statins, fibrates, colchicine or allopurinol.<br />There have been post-marketing reports of drug interactions and central nervous system<br />(CNS) effects (e.g. somnolence and confusion) with the concomitant use of clarithromycin<br />and triazolam. Monitoring t he patient for increased CNS pharmacological effects is<br />suggested .<br />There have been rare reports of clari t hromycin ER ta blets in the stool, many of which have<br />occurred in patients with anatomic (including ileostomy or colostomy) or functional<br />gastrointestinal disorders with shortened GI transit times. In several reports, tablet resid ues<br />have occurred in the context of diarrhoea . It is recommended that patients who experience<br />tablet residue in the stool and no improvement in their condition should be switched to a<br />different clarithromycin formulation (e.g . suspension) or another antibiotic.<br />Special population : Adverse Reactions in Immunocompromised Patients .<br />d. Paediatric populations<br />Clin ical trials have been conducted using clarithromycin paediatric suspension in children 6<br />months to 12 years of age. Therefore, children under 12 years of age should use<br />clari thromycin paediatric suspension. There are insufficient data to recommend a dosage<br />regimen for use of the clarithromycin IV formulation in patients less than 18 years of age.</p><p>Frequency, type and severity of adverse reactions in chi ldren are expected to be the same<br />as in adults.<br />e. Other special populations<br />Immunocompromised patients<br />In AIDS and other in:munocompromised patients treated with the higher doses of<br />clarithromycin over long periods of time for mycobacterial infections, it was often difficult to<br />distinguish adverse events possibly associated with clarithromycin administration from<br />underlying signs of Human Immunodeficiency Virus (HIV) disease or intercurrent illness.<br />In adult patients, the most frequently reported adverse reactions by patients treated with<br />total daily doses of 1000 mg and 2000mg of clarithromycin were: nausea, vomiting, taste<br />perversion, abdominal pai n, diarrhoea, rash, f latu lence, headache, constipation, hearing<br />disturbance, Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic<br />Pyruvate Transaminase (SGPT) elevations. Additional low-frequency events included<br />dyspnoea, insomnia and dry m&middot;outh. The incidences were comparable for patients treated<br />with lOOOmg and 2000mg, but were generally about 3 to 4 times as frequent for those<br />patients who received total daily doses of 4000mg of clarithromycin.<br />In these immunocompromised patients, evaluations of laboratory values were made by<br />analysing those values outside the seriously abnormal level (i.e. the extreme high or low<br />limit) for the specified test. On the basis of these criteria, about 2% to 3% of those patients<br />who received lOOOmg or 2000mg of clarithromycin daily had seriously abnormal elevated<br />levels of SGOT and SGPT, and abnormally low white blood cell and platelet counts. A lower<br />percentage of patients in these two dosage groups also had elevated Blood Urea Nitrogen<br />levels. Slightly higher incidences of abnormal values were noted for patients who received<br />4000mg daily for all parameters except White Blood Cell.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports indicate that the ingestion of large amounts of clarithromycin can be expected to<br />produce gastro-intestinal symptoms. One patient who had a history of bipolar disorder<br />ingested 8 grams of clarithromycin and showed altered mental status, paranoid behaviour,<br />hypokalaemia and hypoxaemia.<br />Adverse reactions accompanying overdosage should be treated by the prompt elimination of<br />unabsorbed drug and supportive measures. As with other macrolides, clarithromycin serum<br />levels are not expected to be appreciably affected by haemodialysis or peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5. Pharmacological Properties:<br />5.1. Pharmacodynamics:<br />ATC Classification:<br />Pharmacotherapeutic group: Antibacterial for systemic use, macrolide ATC-Code: J01FA09<br />Mode of Action:<br />Clarithromycin is an antibiotic belonging to the macrolide antibiotic group. It exerts its<br />antibacterial action by selectively binding to the 50s ribosomal subunit of susceptible<br />bacteria preventing translocation of activitate amino acids. It in hibits the intracellular<br />protein synthesis of susceptible bacteria.<br />The 14-hydroxy metabolite of clarithromycin, a product of parent drug metabolism also has<br />ant imicrobial activity. The metabolite is less active than the parent compound for most<br />organisms, including mycobacterium spp. An exception is Haemophilus influenza where the<br />14-hydroxy metabolite is twofold more active than the parent compound.<br />Clarithromycin is usually .active against the following organ isms in vitro:<br />Gram-positive Bacteria: Staphylococcus au reus (methicillin susceptible); Streptococcus<br />pyogenes (Group A beta-hemolytic streptococci) alphahemolytic streptococci (viridans<br />group); Streptococcus (Diplococcus) pneumoniae; Streptococcus agalactiae; Listeria<br />monocytogenes.<br />Gram-negative Bacteria: Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella<br />(Branhamella) catarrhalis, Neisseria gonorrhoeae; Legionella pneumophila, Bordetella<br />pertussis, Helicobacter pylori; Campylobacter jejuni.<br />Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.<br />Other Organisms: Chlamydia trachomatis; Mycobacterium avium, Mycobacterium leprae;<br />Mycobacterum kansasii; Mycobacterium chelonae; Mycobacterium fortuitum; Mycobacterium<br />intracellulare.<br />Anaerobes: Macro! ide-susceptible Bacteroides fragilis, Clostridium perfringens; Peptococcus<br />species; Peptostreptococcus species; Propionibacterium acnes.<br />Clarithromycin has bactericidal activity against several bacterial strains. The organisms<br />include Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes,<br />Streptococcus agalactiae, Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae, H.<br />pylori and Campylobacter spp.&nbsp;Breakpoints<br />RESCLAR TABLETS 500 mg<br />KSA<br />1.... _d Ju 1&#39;+~.!. ....<br />neopharma<br />The following breakpoints have been established by the European Committee for<br />Antimicrobial Susceptibility Testing (EUCAST).<br />Breakpoints (MIC mg/L)<br />Microorganism Susceptible (:S) Resistant (&gt;)<br />Staphylococcus spp. 1 mg/L 2 mg/L<br />Streptococcus A, B, C 0.25 mg/L 0.5 mg/L and G<br />Streptococcus 0.25 mg/L 0.5 mg/L<br />pneumonia<br />Viridans group<br />streptococcus IE IE<br />Haemophilus spp. 1 mg/L 32 mg/L<br />Moraxella catarrhalis 0.25 mg/L 0.5 mg/L 1<br />Helicobacter pylori 0.25 mg/Ll 0.5 mg/L<br />1 The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish<br />wi ld-type isolates from those with reduces susceptibi lity.<br />&quot;IE&quot; indicates that there is insufficient evidence that the species in question is a good target<br />for therapy with the drug.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.2. Pharmacokinetics:<br />H. pylori is associated with acid peptic disease including duodenal ulcer and gastric ulcer in<br />which about 95% and 80% of patients respectively are infected with the agent. H. pylori is<br />also implicated as a major contribution factor in the development of gastric and ulcer<br />recurrence in such patients.<br />Clarithromycin has been used in small numbers of patients in other treatment regimens.<br />Possible kinetic interactions have not been ful ly investigated. These regimens include:<br />Clarithromycin plus tinidazole and omeprazole; clarithromycin plus tetracycline, bismuth<br />subsalicylate and ranitidine; clarithromycin plus ranitidine alone.<br />Clinical studies using various different H. pylori eradication regimens have shown that<br />eradication of H. pylori prevents ulcer recurrence.&nbsp;Clarithromycin is rapidly and well absorbed from the gastro-intestinal tract after oral<br />administration of Clarithromycin tablets. The microbiologically active metabolite 14-<br />hydroxyclarithromycin is formed by first pass metabolism. Clarithromycin may be given<br />without regard to meals as food does not affect the extent of bioavailability of<br />Clarithromycin tablets. Food does slightly delay the onset of absorption of clarithromycin<br />and formation of the 14-hydroxymetabolite. The pharmacokinetics of clarithromycin are non<br />linear;. however, steady-state is attained within 2 days of dosing. At 250 mg b.i.d. 15-20%<br />of unchanged drug is excreted in the urine. With 500 mg b.i.d. daily dosing urinary<br />excretion is greater (approximately 36%). The 14-hydroxyclarithromycin is the major<br />urinary metabolite and accounts for 10-15% of the dose. Most of the remainder of the dose<br />is eliminated in the faeces, primarily v ia the bile. 5-10% of the parent drug is recovered<br />from the faeces.<br />When clarithromycin 500 mg is given three times daily, the clarithromycin plasma<br />concentrations are increased with respect to the 500 mg twice daily dosage.<br />Clarithromycin provides tissue concentrations that are several times higher than the<br />circulating drug levels. Increased levels have been found in both tonsillar and lung tissue.<br />Clarithromycin is 80% bound to plasma proteins at therapeutic levels.<br />Clarithromycin also penetrates the gastric mucus. Levels of clarithromycin in gastric mucus<br />and gastric tissue are higher when clarithromycin is co-administered with omeprazole than<br />when clarithromycin is administered alone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In acute mouse and rat studies, the median lethal dose was greater than the highest<br />feasible dose for administration (5g/kg).<br />In repeated dose studies, toxicity was related to dose, duration of treatment and species.<br />Dogs were more sensitive than primates or rats. The major clinical signs at toxic doses<br />included emesis, weakness, reduced food consumption and weight gain, salivation,<br />dehydration and hyperactivity. In all species the liver was the primary target organ at toxic<br />doses. Hepatotoxicity was detectable by early elevations of liver function tests.<br />Discontinuation of the drug generally resulted in a return to or toward normal results. Other<br />tissues less commonly affected included the stomach, thymus and other lymphoid tissues<br />and the kidneys. At near therapeutic doses, conjunctival injection and lacrimation occurred<br />only in dogs. At a massive dose of 400mg/kg/day, some dogs and monkeys developed<br />corneal opacities and/or oedema.&nbsp;Fertility and reproduction studies in rats have shown no adverse effects. Teratogenicity<br />studies in rats (Wistar (p.o.) and Sprague-Dawley (p.o. and Lv. )), New Zealand White<br />rabbits and cynomolgous monkeys failed to demonstrate any teratogenicity from<br />clarithromycin. However, a further similar study in Sprague-Dawley rats indicated a low<br />(6%) incidence of cardiovascular abnormalit ies which appeared to be due to spontaneous<br />expression of genetic changes. Two mouse studies revealed a variable incidence (3-30%) of<br />cleft palate and embryonic loss was seen in monkeys but only at dose levels which were<br />clearly toxic to the mothers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1. List of excipients:<br />S. No. Ingredient<br />EXCIPIENTS (CORE TABLETS)<br />1. Microcryta lline Cellulose BP<br />2. Colloidal Anhydrous Si lica BP<br />3. Maize Starch BP<br />4. Povidone BP<br />5. Croscarmellose Sodium BP<br />6 . Purified Talc BP<br />7. St earic Acid BP<br />8 . Magnesium Stearate BP<br />9. Purified Water USP<br />EXCIPIENTS (FILM-COAT)<br />10. Opadry-11 Yellow<br />a) Polyvinyl Alcohol USP<br />b) Talc USP<br />c) Titanium Dioxide USP<br />d) PEG 3350 USNF<br />e) Lecithin USNF<br />f) Quinoline Yellow Lake<br />g) Iron Oxide Yellow USNF<br />11. Purified Water USP<br />~ &middot; ~ L.Jt.e<br />.~ &middot; ~&middot; 04 P.O. Box : 72900 f.<br />~49. Abu Dhabi &middot; U.A.E. &lt;<br />&#39;0 Pharma ~\.~~&middot;<br />Function<br />Diluent<br />Glidant<br />Diluent<br />Binder<br />Disintegrant<br />Glidant<br />Lubricant<br />Lubricant<br />Granulating solvent<br />Coating agent<br />Coating Solvent</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dry place below 30&deg;C.<br />No special precautions are required for storage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Resclar Tablets are packed in blist ers (using Aluminium foil on one side and PVDC-coated<br />PVC film on other side) placed in carton along with leaflet.<br />Pack size: 14&#39;s (7&#39;s blister x 2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>na</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7 .Manufacturer:
Neopharma, Abu Dhabi, UAE
Plot No. Al 89-95,
I ndustrial City of Abu Dhabi (!CAD),
Mussafah, Abu Dhabi, UAE
8. Marketing Authorization Holder:
Neopharma, Abu Dhabi, UAE
Plot No. Al 89-95,
Industrial City of Abu Dhabi (!CAD),
Mussafah, Abu Dhabi, UAE
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                na
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>